Virometix AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Virometix AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10684
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Virometix AG (Virometix) is a biotechnology company that develops vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. The company’s pipeline products include prophylactic and therapeutic vaccines for infectious, respiratory, and oncological diseases; preclinical candidates for a vaccine for respiratory syncytial virus; and two broad-spectrum next-generation vaccines for human papillomavirus or cervical cancer and pneumonia diseases. Its proprietary platforms comprise Synthetic Virus-Like Particle (SVLP) technology for antigen delivery and activation of cells in the immune system; and Synthetic Antigen Mimetic (SAM) technology for antigen design and optimization. Virometix is headquartered in Schlieren, Switzerland.

Virometix AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Virometix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Virometix AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Virometix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Virometix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Virometix AG, Medical Devices Deals, 2012 to YTD 2018 9
Virometix AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Virometix AG, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Virometix Raises Additional USD1.3 Million in Series A Financing 11
Virometix Raises Additional Funds through Venture Financing 12
Virometix Raises Funds through Venture Financing 13
Equity Offering 14
Virometix Raises USD5 Million in Equity Financing 14
Virometix AG – Key Competitors 15
Virometix AG – Key Employees 16
Virometix AG – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Virometix AG, Pharmaceuticals & Healthcare, Key Facts 2
Virometix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Virometix AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Virometix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Virometix AG, Deals By Therapy Area, 2012 to YTD 2018 8
Virometix AG, Medical Devices Deals, 2012 to YTD 2018 9
Virometix AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Virometix Raises Additional USD1.3 Million in Series A Financing 11
Virometix Raises Additional Funds through Venture Financing 12
Virometix Raises Funds through Venture Financing 13
Virometix Raises USD5 Million in Equity Financing 14
Virometix AG, Key Competitors 15
Virometix AG, Key Employees 16

List of Figures
Virometix AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Virometix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Virometix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Virometix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Virometix AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Virometix AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Virometix AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Virometix AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Virometix AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Virometix AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kansai Nerolac Paints Ltd:企業の戦略・SWOT・財務情報
    Kansai Nerolac Paints Ltd - Strategy, SWOT and Corporate Finance Report Summary Kansai Nerolac Paints Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Core-Mark Holding Company, Inc. (CORE):企業の財務・戦略的SWOT分析
    Core-Mark Holding Company, Inc. (CORE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • ARC Resources Ltd (ARX):企業の財務・戦略的SWOT分析
    ARC Resources Ltd (ARX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Symphogen AS-製薬・医療分野:企業M&A・提携分析
    Summary Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics to enhance the lives of patients with cancer and ot …
  • Luye Pharma Group Ltd (2186):製薬・医療:M&Aディール及び事業提携情報
    Summary Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group’s products include paclitaxel liposome, lentinan, sodiu …
  • Standardkessel Baumgarte Holding GmbH:企業の戦略的SWOT分析
    Standardkessel Baumgarte Holding GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • T3D Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary T3D Therapeutics Inc (T3D Therapeutics) is a drug discovery company that develops solutions for the treatment of Alzheimer’s disease and Mild Cognitive Impairment. The company’s pipeline product include T3D-959 an optimal disease remedial therapeutic for the treatment of Alzheimer’s disease. …
  • Nigeria LNG Ltd:企業の戦略的SWOT分析
    Nigeria LNG Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Jordan Trade Facilities Company PLC (JOTF):企業の財務・戦略的SWOT分析
    Jordan Trade Facilities Company PLC (JOTF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • NuVasive Inc (NUVA):医療機器:M&Aディール及び事業提携情報
    Summary NuVasive Inc (NuVasive) is a medical device company that provides minimally invasive, procedurally-integrated spine solutions. The company principally provides Maximum Access Surgery (MAS), a minimally-disruptive surgical platform. MAS platform enables surgeons to perform a range of minimall …
  • ABC arbitrage SA (ABCA):企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Basellandschaftliche Kantonalbank:企業の戦略・SWOT・財務分析
    Basellandschaftliche Kantonalbank - Strategy, SWOT and Corporate Finance Report Summary Basellandschaftliche Kantonalbank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Cobham plc:企業のM&A・事業提携・投資動向
    Cobham plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Cobham plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Raschig GmbH:企業の戦略的SWOT分析
    Raschig GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Flex Ltd (FLEX)-医療機器分野:企業M&A・提携分析
    Summary Flex Ltd (Flex), formerly Flextronics International Ltd, is a provider of technology solutions. It designs, manufactures and provides supply chain services to original equipment manufacturers. The company’s major solutions include disposables, drug delivery, diagnostics devices, automotive e …
  • BBA Aviation plc (BBA):企業の財務・戦略的SWOT分析
    BBA Aviation plc (BBA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sibur Holding:石油・ガス:M&Aディール及び事業提携情報
    Summary Sibur Holding (Sibur) is a vertically integrated gas processing and petrochemicals company. Sibur is one of the major players in Russian petrochemical industry delivering large volumes of associated petroleum gas. The company offers liquefied petroleum gas, natural gas, naphtha and natural g …
  • Petrosibir AB (SHEL B):企業の財務・戦略的SWOT分析
    Summary Petrosibir AB (Petrosibir), formerly Shelton Petroleum AB is an oil and gas company. The company offers exploration and development of oil and gas assets and the resource-rich basins in Russia and Ukraine. It holds Ayazovskoye production license and Rustamovskoye exploration license that cov …
  • Protagen AG:企業の製品パイプライン分析2018
    Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment. The company’s products include multilisa SSC, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyeliti …
  • Intellia Therapeutics Inc (NTLA):企業の財務・戦略的SWOT分析
    Summary Intellia Therapeutics Inc (Intellia Therapeutics) is a genome editing company that develops proprietary curative therapeutics using CRISPR/Cas9 technology. The company develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, hepatitis B infection, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆